In vitro studies demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with UK and South African Variants
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
-
-
Just – Evotec Biologics expanded contract with Department of Defense for manufacturing of monoclonal antibodies
On Jan. 27, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
-
COVID-19 | Diagnostics | Therapeutics | WHO
WHO recommended follow-up care, low-dose anticoagulants for COVID-19 patients
On Jan. 26, 2021, WHO recommends that patients who have COVID-19 – both confirmed and suspected – should…
-
Sorrento announced positive preliminary results of phase 1b study of COVI-MSC for treatment of ICU COVID-19 patients
On Jan. 26, 2021, Sorrento Therapeutics announced positive preliminary results from its Phase 1b study of human allogeneic…
-
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
-
Mateon launched mobile app, ARTIHealthTM, remote for respiratory health assessment
On Jan. 25, 2021, Mateon Therapeutics announced that it was launching its mobile app, ARTIHealthTM, for respiratory health…
-
Medigen’s COVID-19 vaccine announced first participant dosed in phase 2 clinical trial in Taiwan
On Jan. 25, 2021, Medigen Vaccine Biologics and Dynavax Technologies announced that the first participant had been dosed…
-
Biotechnology | Cardiology | Disease | FDA | Therapeutics
FDA approved Aurinia Pharmaceuticals LUPKYNIS (voclosporin) for adults with active lupus nephritis
On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved LUPKYNISTM…
-
Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
-
Cue’s Molecular, point-of-care COVID-19 tests available under HHS and DoD pilot program
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
-
Mammoth Biosciences secured U.S. DoD award to develop CRISPR-based diagnostics and biosurveillance platforms
On Jan. 14, 2021, Mammoth Biosciences announced that it had secured a subcontract with MRIGlobal, the prime contractor…
-
Blood test showed promise for early detection of acute heart transplant rejection
On Jan. 13, 2021, researchers announced they had developed a blood test that could make it possible for…
-
NIAID scientists studied salmonella swimming behavior as clues to infection
On Jan. 13, 2021, National Institutes of Health scientists and their colleagues announced they had identified a S….
-
Mateon announced positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda against COVID-19
On Jan. 13, 2021, Mateon Therapeutics reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against…
-
SIGA announced Public Health Agency of Canada contract to purchase $33 million of Oral TPOXX
On Jan. 13, 2021, SIGA Technologies announced that the Public Health Agency of Canada had awarded a contract…
-
Rising protocol design complexity reported driving rapid growth in clinical trial data volume
On Jan. 12, 2021, the Tufts Center for the Study of Drug Development (Tufts CSDD) reported that ever…
-
Roche’s Xofluza approved by the EC for treatment of influenza, first new influenza antiviral in almost 20 years
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the…
-
Biotechnology | CRISPR | FDA | Therapeutics
FDA cleared initiation of the Editas Medicine’s EDIT-301 clinical trial using CRISPR/Cas12a gene editing
On Jan. 11, 2021, Editas Medicine announced the U.S. Food and Drug Administration (FDA) had cleared the initiation…
-
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics
American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017
On Jan. 8, 2021, the American Cancer Society reported that the death rate from cancer in the U.S….
-
In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation
On Jan. 8, 2021, Pfizer and BioNTech announced results from an in vitro study conducted by Pfizer and…
-
Twist Bioscience supplied Centers for Disease Control and Prevention with custom SARS-CoV-2 synthetic RNA controls
On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…
-
CytoDyn research on critically Ill COVID-19 patients published in Journal of Translational Autoimmunity
On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted…
-
COVID-19 | Neurology | NIH | Therapeutics
NIH study uncovered blood vessel damage and inflammation in COVID-19 patients’ brains but no infection
On Dec. 30, 2020, the NIH researchers announced that an in-depth study of how COVID-19 affects a patient’s…
-
Biotechnology | COVID-19 | FDA | NIH | Therapeutics
Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine
On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…
-
Mateon global study for OT-101/ TGF-inhibitor against COVID-19 treated its first patient
On Dec. 30, 2020, Mateon Therapeutics announced that it had enrolled and treated its first sentinel Part 1…
-
Biotechnology | Disease | FDA | Therapeutics
FDA approved first generic of drug used to treat severe hypoglycemia
On Dec. 28, 2020, the U.S. Food and Drug Administration approved the first generic of glucagon for injection…
-
The Serum Institute of India launched India’s first indigenously developed pneumococcal vaccine
On Dec. 28, 2020, Serum Institute of India announced the launch of India’s first indigenously developed pneumococcal vaccine…
-
AIM ImmunoTech announced availability of ME/CFS clinical trial of drug Ampligen for enrollment to COVID-19 ‘Long Haulers’
On Dec. 24, 2020, AIM ImmunoTech announced that the post-COVID-19 ‘Long Hauler’ portion of the active AMP-511 Expanded…
-
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen
On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to…
-
RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
